Kadir Ulu, Emil Aliyev, Elif Kılıç Könte, Ayşe Tanatar, Şeyma Türkmen, Şeyda Doğantan, Zehra Kızıldağ, Belde Kasap Demir, Deniz Gezgin Yıldırım, Gülçin Otar Yener, Kübra Öztürk, Özge Baba, Ceyhun Açarı, Gülşah Kılbaş, Sema Nur Taşkın, Fatih Haşlak, Şengül Çağlayan, Esra Bağlan, Hatice Adıgüzel Dundar, Özge Başaran, Kenan Barut, Şerife Gül Karadağ, Taner Coşkuner, Hafize Emine Sönmez, Selçuk Yüksel, Mukaddes Kalyoncu, Sevcan A Bakkaloğlu, Erbil Ünsal, Ayşenur Paç Kısaarslan, Yelda Bilginer, Nuray Aktay Ayaz, Özgür Kasapçopur, Seza Özen, Betül Sözeri
OBJECTIVES: The aim of this study is to investigate the effect of anti-interleukin (IL)-1/-6 biologics on systemic juvenile idiopathic arthritis (sJIA)-associated macrophage activation syndrome (MAS). METHODS: Demographic, clinical, and laboratory data of patients followed up with a diagnosis of sJIA-associated MAS assessed from sixteen pediatric rheumatology centers across the country. The clinical and laboratory features of MAS developing while on biological drugs were compared with those without this treatment...
March 5, 2024: Rheumatology